Inhibitors of c-Jun N-terminal kinases (JNK)

• US 20030153560A1
• Filed: 10/23/2001
• Published: 08/14/2003
• Est. Priority Date: 04/23/1999
• Status: Abandoned Application

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Wilke, Susanne, Bemis, Guy W., Salituro, Francesco G., Gao, Huai, Green, Jeremy, Cao, Jingrong, Harrington, Edmund Martin
• Application Number:
  US10/035,823
• Publication Number:
  US 20030153560A1
• Time in Patent Office: Days
• US Class Current: 514/228.2
• CPC Class Codes: C07D 209/40 Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 405/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 417/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: C07F 7/0812 comprising a heterocyclic ring

Abstract

The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

Claims

1. A compound of the formula:

2. The compound according to claim 1, wherein Y is —

(CH₂)—

Q₁ and Q₁ is a substituted phenyl.

3. The compound according to claim 1, wherein the compound is selected from any one of the compounds depicted in Table 1.

4. A pharmaceutical composition comprising an amount of a compound according to any one of claims 1 to 3 effective to inhibit JNK, and a pharmaceutically acceptable carrier.

5. Use of the composition according to claim 4 for the manufacture of a medicament for treating or preventing inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with proinflammatory cytokines in a patient in need thereof.

6. The use according to claim 5, wherein said treating or preventing is for an inflammatory disease selected from acute pancreatitis, chronic pancreatitis, asthma, allergies, or adult respiratory distress syndrome.

7. The use according to claim 5, wherein said treating or preventing is for an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves'"'"' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn'"'"'s disease, psoriasis, or graft vs. host disease.

8. The use according to claim 5, wherein said wherein said treating or preventing is for a destructive bone disorders selected from osteoarthritis, osteoporosis or multiple myeloma-related bone disorder.

9. The use according to claim 5, wherein said wherein said treating or preventing is for a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi'"'"'s sarcoma, or multiple myeloma.

10. The use according to claim 5, wherein said wherein said treating or preventing is for a neurodegenerative disease selected from Alzheimer'"'"'s disease, Parkinson'"'"'s disease, amyotrophic lateral sclerosis, Huntington'"'"'s disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity or hypoxia.

11. The use according to claim 5, wherein said wherein said treating or preventing is for ischemia/reperfusion in stroke or myocardial ischemia, renal ischemia, heart attacks, organ hypoxia or thrombin-induced platelet aggregation.

12. The use according to claim 5, wherein said wherein said treating or preventing is for a condition associated with T-cell activation or pathologic immune responses.

13. The use according to claim 5, wherein said wherein said treating or preventing is for an angiogenic disorder selected from solid tumors, ocular neovasculization, or infantile haemangiomas.